Cargando…

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.

Detalles Bibliográficos
Autores principales:	Michalka, Jozef, Marková, Jana, Gahérová, Ľubica, Maco, Mária, Procházka, Vít, Kořen, Jan, Sýkorová, Alice, Štěpánková, Pavla, Steinerová, Kateřina, Mohammad, Lekaa, Ďuraš, Juraj, Velacková, Barbora, Doležal, Tomáš, Benešová, Kateřina, Lukášová, Marie, Janíková, Andrea, Král., Zdeněk., Móciková, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621554/ http://dx.doi.org/10.1097/01.HS9.0000890984.54786.aa

Ejemplares similares

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry
por: Mocikova, Heidi, et al.
Publicado: (2022)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

P068: A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
por: Marková, Jana, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Brentuximab Vedotin
Publicado: (2012)

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
por: Král, Zdeněk, et al.
Publicado: (2019)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
por: Mociková, Heidi, et al.
Publicado: (2020)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
por: Cranmer, Holly, et al.
Publicado: (2022)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Brentuximab Vedotin Infusion Reaction Management: A Case Study
por: Comer, Holly, et al.
Publicado: (2017)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4lln5vncqc76errucefqhp6p6